Impella LP2.5 vs. IABP in Cardiogenic SHOCK - ISAR-SHOCK


The goal of the trial was to evaluate treatment with an Impella percutaneous left ventricular assist device (LVAD) compared with an intra-aortic balloon pump (IABP) in patients with cardiogenic shock due to acute myocardial infarction (AMI). The Impella device is implanted through a 13 French sheath in the common femoral artery and inserted through the aortic valve into the left ventricle. It provides axial flow to the ascending aorta at a maximum flow rate of 2.5 L/min.